JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yamaguchi, H.
Right arrow Articles by Inui, K.-i.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamaguchi, H.
Right arrow Articles by Inui, K.-i.

Vol. 300, Issue 3, 1063-1069, March 2002

Pharmacokinetic Role of P-Glycoprotein in Oral Bioavailability and Intestinal Secretion of Grepafloxacin in Vivo

Hiroaki Yamaguchi, Ikuko Yano, Hideyuki Saito and Ken-ichi Inui

Department of Pharmacy, Kyoto University Hospital, Faculty of Medicine, Kyoto University, Kyoto, Japan

The purpose of this study was to clarify the contribution of P-glycoprotein to the bioavailability and intestinal secretion of grepafloxacin and levofloxacin in vivo. Plasma concentrations of grepafloxacin and levofloxacin after intravenous and intraintestinal administration were increased by cyclosporin A, a P-glycoprotein inhibitor, in rats. The total body clearance and volume of distribution at steady state of grepafloxacin were significantly decreased to 60 and 63% of the corresponding control values by cyclosporin A. The apparent oral clearance of grepafloxacin was decreased to 33% of the control, and the bioavailability of grepafloxacin was increased to 95% by cyclosporin A from 53% in the controls. Intestinal clearance of grepafloxacin and levofloxacin were decreased to one-half and one-third of the control, respectively, and biliary clearance of grepafloxacin was also decreased to one-third with cyclosporin A in rats. Intestinal secretion of grepafloxacin in mdr1a/1b (-/-) mice, which lack mdr1-type P-glycoproteins, was significantly decreased compared with wild-type mice, although the biliary secretion was similar. Intestinal secretion of grepafloxacin in wild-type mice treated with cyclosporin A was comparable to those in mdr1a/1b (-/-) mice with or without cyclosporin A, indicating that cyclosporin A completely inhibited P-glycoprotein-mediated intestinal transport of grepafloxacin. In conclusion, our results indicated that P-glycoprotein mediated the intestinal secretion of grepafloxacin and limited the bioavailability of this drug in vivo.

0022-3565/02/3003-1063$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
T. Nakano, S. Sekine, K. Ito, and T. Horie
Correlation between Apical Localization of Abcc2/Mrp2 and Phosphorylation Status of Ezrin in Rat Intestine
Drug Metab. Dispos., July 1, 2009; 37(7): 1521 - 1527.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
S. Liu, P. M. Beringer, L. Hidayat, A. P. Rao, S. Louie, G. J. Burckart, and B. Shapiro
Probenecid, but Not Cystic Fibrosis, Alters the Total and Renal Clearance of Fexofenadine
J. Clin. Pharmacol., August 1, 2008; 48(8): 957 - 965.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
C. K. K. Lee, M. P. Boyle, M. Diener-West, L. Brass-Ernst, M. Noschese, and P. L. Zeitlin
Levofloxacin Pharmacokinetics in Adult Cystic Fibrosis
Chest, March 1, 2007; 131(3): 796 - 802.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
H. Sasabe, Y. Kato, T. Suzuki, M. Itose, G. Miyamoto, and Y. Sugiyama
Differential Involvement of Multidrug Resistance-Associated Protein 1 and P-Glycoprotein in Tissue Distribution and Excretion of Grepafloxacin in Mice
J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 648 - 655.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
C G Dietrich, A Geier, and R P J Oude Elferink
ABC of oral bioavailability: transporters as gatekeepers in the gut
Gut, December 1, 2003; 52(12): 1788 - 1795.
[Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
X. Pan, T. Terada, M. Okuda, and K.-I. Inui
Altered Diurnal Rhythm of Intestinal Peptide Transporter by Fasting and Its Effects on the Pharmacokinetics of Ceftibuten
J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 626 - 632.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
G. W. Amsden, A.-M. Whitaker, and P. W. Johnson
Lack of Bioequivalence of Levofloxacin When Coadministered with a Mineral-Fortified Breakfast of Juice and Cereal
J. Clin. Pharmacol., September 1, 2003; 43(9): 990 - 995.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
A. W. Wallace, J. M. Victory, and G. W. Amsden
Lack of Bioequivalence When Levofloxacin and Calcium-Fortified Orange Juice Are Coadministered to Healthy Volunteers
J. Clin. Pharmacol., May 1, 2003; 43(5): 539 - 544.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
A. W. Wallace, J. M. Victory, and G. W. Amsden
Lack of Bioequivalence of Gatifloxacin When Coadministered with Calcium-Fortified Orange Juice in Healthy Volunteers
J. Clin. Pharmacol., January 1, 2003; 43(1): 92 - 96.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.